Medirom Healthcare Acquires 70% Stake in Japan Gene Medicine Corp.
Ticker: MRM · Form: 6-K · Filed: Jul 10, 2024 · CIK: 1819704
Sentiment: neutral
Topics: acquisition, subsidiary, healthcare
TL;DR
Medirom buying 70% of Japan Gene Medicine Corp. on June 30th.
AI Summary
On June 30, 2024, Medirom Healthcare Technologies Inc. entered into a share transfer agreement to acquire 70% of Japan Gene Medicine Corporation (JGMC). This acquisition will make JGMC a subsidiary of Medirom Healthcare Technologies Inc., subject to certain terms and conditions.
Why It Matters
This strategic acquisition expands Medirom's presence in the gene medicine sector, potentially enhancing its service offerings and market position.
Risk Assessment
Risk Level: medium — The acquisition is subject to certain terms and conditions, and the actual integration and success of JGMC as a subsidiary are not yet guaranteed.
Key Numbers
- 70% — Acquisition Stake (Percentage of Japan Gene Medicine Corporation shares Medirom Healthcare Technologies Inc. agreed to acquire.)
Key Players & Entities
- Medirom Healthcare Technologies Inc. (company) — Acquiring company
- Japan Gene Medicine Corporation (company) — Target company
- June 30, 2024 (date) — Date of acquisition agreement
- 70% (dollar_amount) — Percentage of shares to be acquired
FAQ
What is the name of the company Medirom Healthcare Technologies Inc. is acquiring a stake in?
Medirom Healthcare Technologies Inc. is acquiring a stake in Japan Gene Medicine Corporation (JGMC).
What percentage of Japan Gene Medicine Corporation is Medirom acquiring?
Medirom Healthcare Technologies Inc. is acquiring 70% of the shares of Japan Gene Medicine Corporation.
On what date was the share transfer agreement entered into?
The share transfer agreement was entered into on June 30, 2024.
What will be the status of Japan Gene Medicine Corporation after the acquisition?
Japan Gene Medicine Corporation will become one of Medirom Healthcare Technologies Inc.'s subsidiaries.
Are there any conditions to the acquisition?
Yes, the acquisition is subject to certain terms and conditions.
Filing Stats: 1,982 words · 8 min read · ~7 pages · Grade level 18.3 · Accepted 2024-07-10 16:18:09
Filing Documents
- tmb-20240710x6k.htm (6-K) — 27KB
- tmb-20240710xex99d1.htm (EX-99.1) — 51KB
- tmb-20240710xex99d1001.jpg (GRAPHIC) — 4KB
- tmb-20240710xex99d1002.jpg (GRAPHIC) — 4KB
- tmb-20240710xex99d1003.jpg (GRAPHIC) — 58KB
- 0001558370-24-009741.txt ( ) — 170KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: July 10, 2024 MEDIROM HEALTHCARE TECHNOLOGIES INC. By: /s/ Fumitoshi Fujiwara Name: Fumitoshi Fujiwara Title: Chief Financial Officer